Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial ...

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...

For patients with inadequately controlled T2D receiving dulaglutide, switching to tirzepatide is associated with additional HbA1c reduction and weight loss.

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Tirzepatide's uptake was rapid post-launch, surpassing other GLP-1 RAs and SGLT2 inhibitors, while conventional GLMs like metformin and insulin declined. The approval of tirzepatide for type 2 ...

For the current study, 139 patients were randomly assigned to tirzepatide 15 mg or a maximum tolerated dose and 143 to dulaglutide 4.5 mg or a maximum tolerated dose. At baseline, average diabetes ...

Primary endpoint met in the 8-week treatment study (highly statistically significant). Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001).

Mounjaro, an injectable drug used to treat type-2 diabetes and obesity, was launched in India last week. Chemically known as Tirzepatide ... mg) and 15.4 kg weight loss at the lowest dose (5 ...

LLY recently announced price reductions for its obesity drug, Zepbound (tirzepatide ... announced that it is reducing the prices of 7.5 mg and 10 mg single-dose vials of obesity treatment ...